Literature DB >> 22135257

Liquid-based urine cytology as a tool for detection of human papillomavirus, Mycoplasma spp., and Ureaplasma spp. in men.

Shohei Kawaguchi1, Kazuyoshi Shigehara, Toshiyuki Sasagawa, Masayoshi Shimamura, Takao Nakashima, Kazuhiro Sugimoto, Kazufumi Nakashima, Keiichi Furubayashi, Mikio Namiki.   

Abstract

Liquid-based urine cytology (LB-URC) was evaluated for cytological diagnosis and detection of human papillomavirus (HPV), Mycoplasma, and Ureaplasma. Midstream urine samples were collected from 141 male patients with urethritis and 154 controls without urethritis, and sediment cells were preserved in liquid-based cytology solution. Urethral swabs from urethritis patients were tested for the presence of Neisseria gonorrhoeae and Chlamydia trachomatis. Papanicolaou tests were performed for cytological evaluation. HPV, Mycoplasma, and Ureaplasma genomes were determined by PCR-based methods, and localization of HPV DNA in urothelial cells was examined by in situ hybridization (ISH). The β-globin gene was positive in 97.9% of LB-URC samples from urethritis patients and in 97.4% of control samples, suggesting that high-quality cellular DNA was obtained from the LB-URC samples. HPV DNA was detected in 29 (21.0%) urethritis cases and in five (3.3%) controls (P < 0.05). HPV type 16 (HPV 16) was most commonly found in urethritis patients. Cytological evaluations could be performed for 92.1% of urethritis patients and 64.3% of controls. Morphological changes suggestive of HPV infection were seen in 20.7% of the HPV-positive samples, and ISH demonstrated the presence of HPV DNA in both squamous and urothelial cells in HPV-positive samples. Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma parvum, and Ureaplasma urealyticum were detected in 14.5%, 10.9%, 6.5%, and 12.3% of urethritis patients, respectively. The prevalence rates of these microorganisms (except Ureaplasma parvum) were significantly higher in urethritis cases than controls (P < 0.05). LB-URC is applicable for detection of HPV, Mycoplasma, and Ureaplasma. HPV infection occurs in urothelial cells, especially in gonococcal urethritis.

Entities:  

Mesh:

Year:  2011        PMID: 22135257      PMCID: PMC3264174          DOI: 10.1128/JCM.05219-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  [Leucoplakia vesicae in females: diagnosis and treatment].

Authors:  A I Neĭmark; E V Il'inskaia; R N Lebedeva; T C Taranina
Journal:  Urologiia       Date:  2009 Mar-Apr

Review 2.  Age-specific prevalence of infection with human papillomavirus in females: a global review.

Authors:  Jennifer S Smith; Amy Melendy; Rashida K Rana; Jeanne M Pimenta
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

Review 3.  Papillomavirus infections--a major cause of human cancers.

Authors:  H zur Hausen
Journal:  Biochim Biophys Acta       Date:  1996-10-09

Review 4.  Prevalence of HPV infection among men: A systematic review of the literature.

Authors:  Eileen F Dunne; Carrie M Nielson; Katherine M Stone; Lauri E Markowitz; Anna R Giuliano
Journal:  J Infect Dis       Date:  2006-09-12       Impact factor: 5.226

5.  A thin-layer, liquid-based pap test for mass screening in an area of China with a high incidence of cervical carcinoma. A cross-sectional, comparative study.

Authors:  Qinjing Pan; Jerome L Belinson; Ling Li; Robert G Pretorius; You Lin Qiao; Wen Hua Zhang; Xun Zhang; Ling Ying Wu; Sou De Rong; Yun Tian Sun
Journal:  Acta Cytol       Date:  2003 Jan-Feb       Impact factor: 2.319

6.  Comparison of multiplex PCR assay with culture for detection of genital mycoplasmas.

Authors:  Kathleen A Stellrecht; Amy M Woron; Nada G Mishrik; Richard A Venezia
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

7.  Risk factors for anogenital human papillomavirus infection in men.

Authors:  Carrie M Nielson; Robin B Harris; Eileen F Dunne; Martha Abrahamsen; Mary R Papenfuss; Roberto Flores; Lauri E Markowitz; Anna R Giuliano
Journal:  J Infect Dis       Date:  2007-09-17       Impact factor: 5.226

8.  Human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection.

Authors:  Rika Yamada; Toshiyuki Sasagawa; Leah W Kirumbi; Alan Kingoro; Dominic K Karanja; Michael Kiptoo; George W Nakitare; Hiroshi Ichimura; Masaki Inoue
Journal:  J Med Virol       Date:  2008-05       Impact factor: 2.327

9.  A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping.

Authors:  Tsuyoshi Asato; Toshiyuki Maehama; Yutaka Nagai; Koji Kanazawa; Hiroshi Uezato; Ken-Ichi Kariya
Journal:  J Infect Dis       Date:  2004-04-26       Impact factor: 5.226

10.  Human papillomavirus infection and risk determinants for squamous intraepithelial lesion and cervical cancer in Japan.

Authors:  T Sasagawa; Y Dong; K Saijoh; S Satake; M Tateno; M Inoue
Journal:  Jpn J Cancer Res       Date:  1997-04
View more
  2 in total

1.  Association of Righ-Risk Human Papillomavirus and Ureaplasma parvum Co-Infections with Increased Risk of Low-Grade Squamous Intraepithelial Cervical Lesions.

Authors:  Isabella Harumi Yonehara Noma; Cristiane Suemi Shinobu-Mesquita; Tamy Taianne Suehiro; Fabricio Morelli; Maria Vitória Felipe De Souza; Edilson Damke; Vânia Ramos Sella Da Silva; Marcia Edilaine Lopes Consolaro
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

2.  Prevalence of human papillomavirus infection in the oropharynx and urine among sexually active men: a comparative study of infection by papillomavirus and other organisms, including Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma spp., and Ureaplasma spp.

Authors:  Kazufumi Nakashima; Kazuyoshi Shigehara; Shohei Kawaguchi; Akira Wakatsuki; Yoshitomo Kobori; Kazuyoshi Nakashima; Yasunori Ishii; Masayoshi Shimamura; Toshiyuki Sasagawa; Yasuhide Kitagawa; Atsushi Mizokami; Mikio Namiki
Journal:  BMC Infect Dis       Date:  2014-01-27       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.